Plain-language guides for everything the clinic forgot to tell you. Written from what 372K GLP-1 users have actually figured out.
The starter dose is roughly 1/10 of the therapeutic dose. Week one is your body learning the signal, not the medication failing.
Nausea, constipation, reflux. The strategies that work for 74–84% of GLP-1 users, and which ones to skip.
Slow titration isn't a mistake. It's the only path to a tolerable therapeutic dose. The science, explained simply.
Fatigue on GLP-1 is common and almost always fixable. The top three culprits and what to try first.
What trial data and post-market reports show from the starter dose through maintenance, dose by dose. Reassurance, not triage.
Step-by-step technique, site rotation strategy, and the common mistakes, plus why the needle fear usually disappears.
The 30-minute fasting rule, the 6 AM alarm hack, and everything else you need to know about oral GLP-1.
Daily GLP-1 means a different rhythm than weekly. Adherence strategies, what to expect, and why streak tracking matters.
Same GLP-1 family, four very different labels. What the FDA, the head-to-head trials, and your insurance actually say.
$900 to $1,400 at list, very different through insurance, and a Medicare GLP-1 Bridge launching July 1. What people actually pay and what just changed.
Same molecules, different labels. What semaglutide and tirzepatide actually do for glucose, what the CV and kidney trials show, and when the prescribing team picks one.
GLP-1 quietly turns down thirst. Why electrolytes, not water, are usually the missing piece on day four.
Without intentional protein intake, up to 40% of weight lost can be muscle. The fix is simpler than you think.
Which foods cause nausea, how the app spots patterns, and what the community eats when nothing sounds good.
Protein-first, no calorie counting, no meal plans. The principles four medical societies converged on in 2025.
The constant mental soundtrack about food just stops. The most transformative experience people describe on GLP-1, and the grief that can follow.
The identity shift, the lost coping mechanisms, and what the largest safety review actually found about suicide risk.
Mood swings, emotional flatness, and the injection-day pattern. What's normal and what to watch for.
The "easy way out" myth, the "forever" fear, and five other common beliefs examined against clinical evidence.
Three different conversations get called the same thing. What the evidence says about each, and what the chronic-disease framing actually means.
FDA warnings, recall history, and how to verify pharmacy legitimacy. What you need to know before choosing compounded.
80% of patients maintain weight on lower doses. The lowest-effective-dose strategy and how to find yours.
A meta-analysis of 27 RCTs shows insulin resistance improvement and hormonal benefits. But GLP-1 is NOT FDA-approved for PCOS.
The wins that matter most don't have a number. From fitting into airplane seats to eating ice cream in public without being judged.
Up to 40% of weight lost on a GLP-1 can be muscle. The medication doesn't solve that on its own. What the four-society Joint Advisory actually says.
Plateaus are universal, and even a 7-month stall can break. What the clinical trials and community experience actually show.
The biology of weight regain, the taper strategy, and why the chronic-disease comparison actually helps.
Hair loss affects 1–6% of users and is caused by rapid weight loss, not the medication itself. The timeline and what helps.
Suddenly can't stand chicken? Sweets taste metallic? Up to 85% of users report major food-preference shifts. Here's why.
The patterns you can't see without data, and why imperfect tracking still counts.
No articles in this topic yet.